anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There were no indications of gastrointestinal or other toxic effects due to oral administration of Proquin XR tablets to male and female beagle dogs at doses up to 1000 mg/day for 28 days (approximately 2.6- and 4.9-fold [male and female dogs, respectively] the recommended therapeutic dose based upon AUC measures of systemic exposure).

Ciprofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested. (See WARNINGS)

Crystalluria, sometimes associated with secondary nephropathy, occurs in laboratory animals dosed with the fluoroquinolone class of drugs. This is primarily related to the reduced solubility of ciprofloxacin under alkaline conditions, which predominate in the urine of test animals. In contrast, crystalluria is rare in man since human urine is typically acidic.

In mice, concomitant administration of nonsteroidal anti-inflammatory drugs such as phenylbutazone and indomethacin with quinolones has been reported to enhance the CNS stimulatory effects of quinolones.

Ocular toxicity seen with some related drugs has not been observed in ciprofloxacin-treated animals. There was no indication of ocular toxicity in the dog study cited above.
<P>PROBLEM TO BE SOLVED: To provide an excellent antibacterial agent manifesting a specific antibacterial activity to Propionibacterium acnes.  <P>SOLUTION: The invention relates to the antibacterial agent based on a discovery that a tocopheryl phosphate and/or its salt manifest the specific antibacterial activity to the Propionibacterium acnes. The antibacterial agent containing tocopheryl phosphate and/or its salt manifest an excellent antibacterial activity to acne bacteria which is bacteria causing pimple. The antibacterial agent manifests a synergy effect by using with another kind of antibacterial agent. The antibacterial agent manifests an ameliorating effect on pimple in a practical test on the people with pimples. The antibacterial agent can be used for a cosmetic, a quasi-drug, medicine.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Peripheral neuropathy (PN) is a prevalent and debilitating complication of obesity, prediabetes, and type 2 diabetes, which remains poorly understood and lacks disease-modifying therapies. Fortunately, diet and/or exercise have emerged as effective treatment strategies for PN. Here, we examined the impact of caloric restriction (CR) and high-intensity interval training (HIIT) interventions, alone or combined (HIIT-CR), on metabolic and PN outcomes in high-fat diet (HFD) mice. HFD feeding alone resulted in obesity, impaired glucose tolerance, and PN. Peripheral nerves isolated from these mice also developed insulin resistance (IR). CR and HIIT-CR, but not HIIT alone, improved HFD-induced metabolic dysfunction. However, all interventions improved PN to similar extents. When examining the underlying neuroprotective mechanisms in whole nerves, we found that CR and HIIT-CR activate the fuel-sensing enzyme AMPK. We then performed complimentary in vitro work in Schwann cells, the glia of peripheral nerves. Treating primary Schwann cells with the saturated fatty acid palmitate to mimic prediabetic conditions caused IR, which was reversed by the AMPK activator, AICAR. Together, these results enhance our understanding of PN pathogenesis, the differential mechanisms by which diet and exercise may improve PN, and Schwann cell-specific contributions to nerve insulin signaling and PN progression.
Relocating medical devices for more efficient preventative maintenance. In one embodiment, a computer receives packets related to activity of medical devices, which are transmitted over a communication network. The computer performs deep packet inspection (DPI) of the packets, and calculates, based on results of the DPI, extents of utilization of each of the medical devices since receiving the most recent preventative maintenance. The computer identifies, based on the extents, first and second medical devices that are scheduled for upcoming preventative maintenance and are located in first and second rooms, respectively. An extent of utilization of the first medical device is below a predetermined threshold, and an extent of utilization of the second medical device is above the predetermined threshold. The computer recommends moving the first medical device to the second room and moving the second medical device to the first room.
Although therapy with direct-acting antiviral (DAA) agents achieves high hepatitis C virus (HCV) cure rates and is forgiving of missed doses, certain patient populations, such as people who inject drugs (PWID), are often denied therapy because of a perceived high risk of nonadherence. However, a relationship between adherence to DAAs for various patient populations and efficacy has not been well defined. The lack of a standardized method for evaluating adherence complicates making comparisons between studies, making it difficult to develop and implement novel measures that may improve adherent behavior. Traditional methods for assessing adherence may overestimate medication adherence, while newer, technology-based methods may assist with accurately assessing and maintaining patient adherence to therapy. Data demonstrate that special populations of patients with HCV, such as PWID, can be successfully treated, with relatively high rates of sustained virologic response (SVR) despite less-than-optimal adherence. While rates of adherence, and subsequently SVR, can be improved, antiviral therapy should not be withheld because of fear of nonadherence. This article addresses medication adherence and forgiveness of DAA regimens, such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir, in different patient populations with HCV. Considerations in evaluating adherence in HCV therapy and available methods for assessing adherence are detailed.
The intranasal route enables direct delivery of multiple substances from the nose to the brain, through olfactory and trigeminal pathways, bypassing the blood-brain barrier and avoiding systemic absorption. Despite the potential of this route, the various administration approaches make data reproducibility and interpretation challenging, emphasizing the necessity to establish a consistent methodology. Considering this, the aim of our study was to assess and compare the distribution of two dye volumes (30 µl and 50 µl) in the nasal cavity of rat cadavers. We employed three distinct methods of intranasal delivery: nose drops, by pipette tip, or cannula inserted into the nasal cavity. The results indicated that for both volumes, using the nose drops and the pipette tip methods, the dye dispersion occurred mainly in the vestibule, respiratory and olfactory regions, without reaching the olfactory bulbs. Using the cannula method, the deposition predominantly occurred in the respiratory and olfactory regions, with the dye reaching 66.7% and 100% of the olfactory bulbs, respectively, to low and high volume. Furthermore, the results demonstrated differences between the two volumes, in the pharynx, larynx, trachea, septal window, and incisive papilla, where an increased dye presence was observed with the 50 µl instillation across all three methods. According to our results, the intranasal delivery with a cannula was the most effective method for dye deposition in the olfactory region. However, further studies in live animals will be necessary to determine and refine the administration method that consistently allows specific deposition in the olfactory system.
The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by a subset of murine plasmacytoid DCs (pDCs) in tumor-draining LNs, where it can potently activate Foxp3 regulatory T cells (Tregs). We now show that IDO functions as a molecular switch in tumor-draining LNs, maintaining Tregs in their normal suppressive phenotype when IDO was active, but allowing inflammation-induced conversion of Tregs to a polyfunctional T-helper phenotype similar to proinflammatory TH17 cells when IDO was blocked. In vitro, conversion of Tregs to the TH17-like phenotype was driven by antigen-activated effector T cells, and required IL-6 produced by activated pDCs. IDO regulated this conversion by dominantly suppressing production of IL-6 in pDCs, in a GCN2-kinase dependent fashion. In vivo, using a model of established B16 melanoma, the combination of an IDO-inhibitor drug plus anti-tumor vaccine caused upregulation of IL-6 in pDCs and in situ conversion of a majority of Tregs to the TH17 phenotype, with marked enhancement of CD8 +  T cell activation and anti-tumor efficacy. Thus, Tregs in tumor-draining LNs can be actively re-programmed in vitro and in vivo into T-helper cells, without the need for physical depletion, and IDO serves as a key regulator of this critical conversion.
A blend comprises menthyl 3-oxocarboxylic acid ester derivatives; at least one further substance (c) having a physiological cooling action, which optionally causes a flavor effect; at least one aroma substance (d) without a physiological cooling action; and at least one substance (e) without a physiological cooling action and having a trigeminal or salivatory action. A blend comprises at least one compound (a) of menthyl 3-oxocarboxylic acid esters of the formulae (Ia) and/or (Ib); a compound (b) of at least one menthyl 3-oxocarboxylic acid esters of the formulae (IIa)-(IIf); at least one further substance (c) having a physiological cooling action, which optionally causes a flavor effect; at least one aroma substance (d) without a physiological cooling action; and at least one substance (e) without a physiological cooling action and having a trigeminal or salivatory action. Provided that when the compound (a) is L-menthyl-3-oxobutyrate and the aroma substances (d) comprises L-menthyl-3-hydroxybutyrate, then the blend does not comprise a reducing agent for L-menthyl-3-oxobutyrate. R 1-R 5hydrogen or 1-4C (un)saturated hydrocarbon residue. Independent claims are included for the following: (1) a preparation comprising the blend, where the preparation is consumed for nutrition, for pleasure or for oral hygiene, or pharmaceutical or cosmetic preparation, and which achieve a physiological cooling action on the skin and/or mucous membranes; and (2) a therapeutic or non-therapeutic method for achieving a physiological cooling action on skin and/or mucous membranes, involving applying the compound (Ia) and/or (Ib), the blend, or a preparation comprising the compound (Ia) and/or (Ib), onto the skin and/or mucous membranes. [Image] [Image] [Image] ACTIVITY : None given. MECHANISM OF ACTION : None given.
A dynamical anesthetization management system includes an interface selecting module, a processor and a display. The interface selecting module is configured to input an interface selecting command. The interface selecting module includes a display area, a hidden area and a plurality of information column. The information column is configured to disposed on the display area or hidden area. The processor is connected to the interface selecting module and produce a display interface based on the selecting command. The display is connected to the processor and configured to display the display interface. The information column disposed on the display area would be display on the display interface. The information column disposed on the hidden area would not be display on the display interface.
In 4 study sessions, no intervention will be performed. As with the two experimental arms, the 4 study sessions are at least one month apart and consist of 3 consecutive study days on which no intervention will be performed. This arm serves as a time control group.
This study analyzed the evolution of chronic pelvic pain, defined by the different map of myofascial trigger points assets presents the patient with medical treatment compared to treatment with radiofrequency endocavitary electrode MJS. The initial evaluator analyzed by the NIH-CPSI Scale questionnaire and symptoms of chronic pelvic pain Stanford Protocol for female or male quality of life of the patient before the doctor or radio frequency and a month since treatment. the patient to the Principal Investigator, specialist physiotherapist, who appreciates tenderness the presence of a taut band with a map of pain in endopelvic and exopelvic muscles, determining the activation of myofascial trigger points in each is derived. The Principal Investigator proceeds to address each active myofascial trigger points with the MJS electrode four 20-minute sessions twice a week. The MJS has a curved end pressure which favors the compression point plus the location and accurate approach Radiofrequency pathological point as outstanding feature. The high specificity of myofascial treatment offered by the MJS electrode involves no danger, besides having the computer screen conductivity meter and a temperature sensor on the head to control both parameters in real time during the treatment session
PROBLEM TO BE SOLVED: To obtain a nasal and oral spray which, when administered to the nasal mucosa or the oral mucosa, can exhibit excellent effect of alleviating various inflammation symptoms such as pollinosis and stomatitis by using chitin as the active ingredient. SOLUTION: The chitin herein mentioned means poly-N-acetyl-D-glucosamine obtained from the exoskeletons of Crustacea and of beetles and the calcified internal shells of cuttlefishes and derivatives thereof. The derivatives include deacetylated chitin and chitosan. The chitin has a degree of deacetylation of desirably 20% or below, more desirably 5% or below. Examples of the forms of the chitin used in the nasal and oral spray include powders, granules and short fibers, and especially a powder having a particle size distribution having an effective particle diameter of 20-250 μm is desired, because it can deposit on the nasal mucosa in a high proportion when administered through the nostril. The chitin powder may be a commercially one or a powder prepared by dissolving a molding in a solvent, forming the solution into a desired molding and grinding this molding.  Especially, a chitin powder obtained from a molding, such as a sponge or granules, made from the powder containing the solvent is desirable.
PURPOSE: An iron oxide nano particle in which non-polymer bio molecules are introduced to a surface modifier and a cancer diagnosis and treatment composition including thereof are provided to improve delivery of oxide nano particles to target organ. CONSTITUTION: An iron oxide nano particle comprises iron oxide based core particles, a shell coated with soluble material which is selected from ATP, NAD, ADP, AMP and NADP, and gluconic acid combined in surface of the shell. The soluble are ATP. Fluorescent probes are additionally combined with surfaces of the nano particles. The fluorescence probes are chlorotoxin. A weight ratio of the gluconic acid to the iron oxide based core particle which is coated with ATP is 1:0.3-1:3. A diameter of the nano particle is 5-300 nano meters.
This is a prospective observational cohort study with 120 healthy community-dwelling elderly people in a single center (SMG-SNU Boramae Medical Center). Individual follow-up will last 4 years. Elderly people (≥ 65 years old) who are community-dwellers and able to walk with or without assistive devices) will be included. Sarcopenia can be divided by two stages: 1) possible sarcopenia (PS) defined by low handgrip strength and/or low gait speed and 2) sarcopenia (SA) confirmed by low handgrip strength and/or low gait speed and low muscle mass by the consensus report of the Asian working group for sarcopenia. No sarcopenia (NS) group is added to this classification, and the study participants are classified into three groups (NS, PS, and SA) after the screening tests. All outcome variables will be collected at baseline, 2 and 4 years. However, L-S spine MRI for lumbar paraspinal muscle quantity and quality will be performed only at baseline.

Data will be collected using a standardised data entry form and entered into the data management system. The intention-to-treat principle will be used for data analysis. Participant characteristics will be described using means and standard deviations for continuous data and frequencies and percentages for categorical data. The three groups will be compared using an analysis of variance (ANOVA) or the non-parametric equivalence Kruskal-Wallis test if required. To compare paired data (intra-group) between two different points, we will use repeated-measures ANOVA and Friedman tests for continuous and non-parametric data, respectively.
The prevalence of xerostomia varies high in patients with chronic hemodialysis (HD), and the decreased saliva flow rate due to various mechanisms is the main factor in its development. The significant decrease in saliva flow due to the atrophy and fibrosis of the salivary glands in HD patients is further affected by the restriction in fluid intake. The use of drugs such as antidepressants, antipsychotics, antihistamines, antihypertensives, aspirin, benzodiazepines, opioids and proton pump inhibitors also leads to hyposalivation and xerostomia. Thirst is common in chronic HD patients due to both volumetric and osmometric causes but the primary mechanism is osmometric. The osmolarity of the extracellular fluid increases with the dietary salt and the hypothalamus is stimulated by the shrinkage of the osmoreceptor cells, leading to the desire to ingest liquids. Volumetric thirst develops secondary to water and salt loss and the resultant stimulation of cardiac baroreceptors, with the cardiac return volume decreasing gradually towards the end of the HD session. Increased interdialytic weight in HD patients causes increased risk of death due to cerebrovascular events and cardiovascular diseases and leads to an increase in morbidity and mortality together with a deterioration of the patient's quality of life. Interdialytic weight gain (IWG) causes incompliance with fluid control as a result of the secondary excessive consumption of liquid and food and is an important condition.
Surgery is a standard treatment for early-stage gastrointestinal cancers, often preceded by neoadjuvant chemo(radio)therapy or followed by adjuvant therapy. While leading to cure in a proportion of patients, it has some drawbacks such as intra/post-operative complications, mutilation and life-long functional sequelae. Further to the unprecedented efficacy data from studies of immune checkpoint inhibitors for advanced mismatch repair deficient/microsatellite instable (dMMR/MSI-H) tumours, a strong interest has recently emerged for the investigation of such agents in the neoadjuvant setting. Although limited by the exploratory design and small sample size, trials of neoadjuvant immune checkpoint inhibitors for early-stage dMMR/MSI-H gastrointestinal cancers have consistently reported complete response rates ranging from 70 % to 100 %. As a result, the question has arisen as to whether surgery is still needed or organ-preserving strategies should be offered to this especially immuno-sensitive population. In this article, we discuss the available evidence for neoadjuvant immune checkpoint inhibitors in dMMR/MSI-H gastrointestinal cancers and analyse opportunities and challenges to the implementation of non-operative management approaches in this setting.
Participants will receive two of six sunscreens (A, B, C, D, E, and F) at Visit 1 (Day 1) to apply to whole lower legs (1 sunscreen per lower leg), between the knee and ankle. Participant will then select one of the two sunscreens randomly assigned to lower legs and apply the selected sunscreen to full face. After lower legs and facial applications are completed, a trained designee will delineate six 4 centimeters (cm)\*4 cm test sites on the participants' volar forearms (3 test sites per volar forearm). The six sunscreens will be randomly assigned to the six test sites at a dose of 2.00 +- 0.05 milligrams per centimeter square (mg/cm\^2) using a 1cc tuberculin syringe (without a needle) and a clean finger cot for approximately 20 to 50 seconds and applied by a trained designee.
A composition for inhibiting ketohexokinase, for example, ketohexokinase-C (KHK-C) activity, may include a plant extract exhibiting at least IC50 (i.e., 50% KHK-C inhibition at a concentration in the range of from about 0.1 [mu]g/mL to about 1000 [mu]g/mL. The composition may be in a form suitable for oral ingestion. A method for inhibiting KHK-C activity in a subject may include administering a plant extract that exhibits at least 50% KHK-C inhibition at a concentration from about 0.1 [mu]g/mL to about 1000 [mu]g/mL. The administering may be done to treat or prevent at least one of sugar addiction, obesity, or metabolic syndrome. The administering may be done to provide a diminished craving in the subject from at least one member selected from the group consisting of craving of sugar, fructose, fructose-containing sugars, carbohydrates, and combinations thereof. The subject may be pre-diabetic, diabetic and or insulin resistant.
PURPOSE: A composition containing Morus bombycis Koidz extract for preventing and treating arthritis is provided to suppress osteoclast and cytokine generation. CONSTITUTION: A composition for preventing and treating arthritis contains Morus bombycis Koidz extract as an active ingredient. The Morus bombycis Koidz extract is isolated by hot water or solvent. The hot water extract is prepared by heating at 100-120°C for 2-3 hours. The solvent extraction is performed by ultrasoncation using a mixture solvent of water and ethanol. The composition is a pharmaceutical composition or food composition.
PURPOSE:To obtain a cosmetic capable of coloring in a temperature region of human skin, capable of keeping perfect moisture-retaining property while retaining priority on appearance and further having effectiveness of beauty by making cholesteric liquid crystal retain using an extract of Ficus awketosang Makino as a medium. CONSTITUTION:A cosmetic obtained by making cholesteric liquid crystal retain (e.g. liquid crystal composition obtained by blending two or more kind of ester cholesteryl oleate, cholesteryl butylate, etc., with cholesteryl 12-hydroxystearate) using an extract of Ficus awketosang Makino (obtained by drying fruit of a plant named as KANTEN ITABI), preferably further containing glycerin. Water extract of Ficus awketosang Makino is used at an amount of 0.1-5.0wt.%, expressed in terms of dried weight or 3-10wt.%, when glycerin is blended. Coloring of the liquid crystal is made clear by using a liquid containing Ficus awketosang Makino. Thereby feeling in use is not lowered and moisture- retaining property can be enhanced.
The present invention relates to the field of medicine preparation, and provides a preparation and a preparation method thereof. The preparation is rapidly disintegrated or dissolved in the oral cavity. The present invention takes Eudragit E-100, lactose, mannitol, low-replaced hyprolose, magnesium stearate and menthol as materials, adopts a wet granulating and tabletting method, and respectively takes salbutamol, salbutamol sulphate, salbutamol, and hydrochloride, sulfate, tartrate, oxalate, citrate, maleate, etc. of salbutamol as medicine. All the materials are made into tablets which are rapidly disintegrated and dissolved in the oral cavity. The present invention does not need particular apparatuses, adopts a common tabletting machine, and has the advantages of simple technology and low cost.
A pyroglutamic acid composition comprising pyroglutamic acid enhances the umami sensation of food products when topically applied. The pyroglutamic acid may be derived from a food product such as a tuber product or potato. The pyroglutamic acid may be in the form of L-pyroglutamic acid, D-pyroglutamic acid, or mixtures thereof. Topical addition of pyroglutamic acid in an amount of between about 300 to about 12,000 ppm onto a food product enhances both the salty and umami taste perceptions simultaneously. Other seasonings may also be simultaneously applied to the food product as part of the pyroglutamic acid composition. Alternatively, additional seasoning may be applied apart from the addition of the pyroglutamic acid in a separate step.